Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study

1. Lee, S.J.
2. Richardson, P.G.
3. Sonneveld, P.
4. Schuster, M.W.
5. Irwin, D.
6. San Miguel, J.-F.
7. Crawford, B.
8. Massaro, J.
9. Dhawan, R.
10. Gupta, S.
11. Anderson, K.C.